6572 Stock Overview
PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PlexBio Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$11.55 |
| 52 Week High | NT$20.00 |
| 52 Week Low | NT$11.20 |
| Beta | 0.25 |
| 1 Month Change | -8.70% |
| 3 Month Change | -16.91% |
| 1 Year Change | -39.84% |
| 3 Year Change | -45.00% |
| 5 Year Change | -21.43% |
| Change since IPO | -72.03% |
Recent News & Updates
Shareholder Returns
| 6572 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | -1.3% | -2.6% | -2.6% |
| 1Y | -39.8% | -0.2% | 25.9% |
Return vs Industry: 6572 underperformed the TW Medical Equipment industry which returned -0.2% over the past year.
Return vs Market: 6572 underperformed the TW Market which returned 25.9% over the past year.
Price Volatility
| 6572 volatility | |
|---|---|
| 6572 Average Weekly Movement | 2.8% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.4% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6572 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6572's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | n/a | Dean Tsao | www.plexbio.com |
PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation extraction kits; IntelliPlex platform that is designed for pCode technology with for sample-to-answer multiplexing assays; oncology kits for lung cancer and mutation detection, as well as rearrangements; IntelliPlex SARS-CoV-2 detection test kits/flu kits and IntelliPlex SARS-CoV-2 variant analysis kits; and pCode coupling buffer sets. PlexBio Co., Ltd.
PlexBio Co., Ltd. Fundamentals Summary
| 6572 fundamental statistics | |
|---|---|
| Market cap | NT$1.20b |
| Earnings (TTM) | -NT$52.84m |
| Revenue (TTM) | NT$179.94m |
6.7x
P/S Ratio-22.7x
P/E RatioIs 6572 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6572 income statement (TTM) | |
|---|---|
| Revenue | NT$179.94m |
| Cost of Revenue | NT$124.56m |
| Gross Profit | NT$55.38m |
| Other Expenses | NT$108.22m |
| Earnings | -NT$52.84m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.51 |
| Gross Margin | 30.78% |
| Net Profit Margin | -29.37% |
| Debt/Equity Ratio | 0% |
How did 6572 perform over the long term?
See historical performance and comparison